By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel's net takeaway is that while Oscar Health's growth is undeniable, its path to profitability and high margins is uncertain and risky, with significant execution challenges and regulatory constraints.
Risk: Regulatory constraints, particularly the 80% Medical Loss Ratio cap, and potential medical cost inflation and utilization shocks pose significant risks to Oscar Health's profitability and margin expansion.
Opportunity: Successfully scaling its employer-funded plans and monetizing its tech stack as a high-margin SaaS revenue stream could provide a path to higher margins and valuation for Oscar Health.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Oscar Health's growth potential in health insurance remains underrated.
The company is in the middle of a massive profit inflection.
Its stock trades at a very low price if it keeps up this growth trajectory.
When looking for multibagger stocks, it is best to hunt in industries with huge addressable markets. Even if a company is the best brand in a sector, but that sector only has $100 million in annual spending and isn't growing, there will be a limit to the company's addressable market unless it can invent new products to serve customers.
One sector where size is not an issue is healthcare, specifically health insurance. Health insurance premiums in the United States are estimated at $1.6 trillion per year, and spending is set to increase faster than GDP due to the country's aging population.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Oscar Health (NYSE: OSCR) is a magnificent healthcare stock taking market share through its technology-focused health insurance offering. Here's why the rapid grower is set to deliver market-beating returns for years to come.
The health insurance market changed in 2010 with the enactment of the Affordable Care Act (ACA), which created marketplaces that allow individuals to purchase their own health insurance through a regulated platform each year.
It got off to a bumpy start, but individual payors through the ACA now number around 20 million, making it a meaningful portion of the sector. Oscar has been a big part of this growth with its sole focus on the individual payor market today. Total paying members through Oscar Health plans reached 3.2 million last quarter, an over 50% boost from 2 million in the same quarter a year ago. This is growing much faster than the overall ACA market, indicating that Oscar Health is gaining significant market share.
Why? Because Oscar Health offers a better customer experience with its cloud-first digital platform, saving time and headaches (literally) for its health insurance stakeholders. Now, it is making a big push to transform the employer-led health insurance market to individual contribution plans. These plans allow employers to subsidize employee health insurance, but instead of putting everyone in homogeneous plans, people can use the funds to shop on the ACA marketplace, potentially choosing Oscar insurance.
Management sees a huge addressable market for individual employer-funded plans, potentially reaching 75 million small and mid-sized businesses. With only 3.2 million members last quarter, Oscar Health is guiding for $19 billion in revenue at the high end for 2026. If it can reach 10 million or more customers, that could mean $50 billion or more in annual premiums, depending on where healthcare inflation heads in the years ahead.
Health insurers are highly regulated under the ACA marketplace, with a maximum loss ratio of 80% each year, leaving 20% of their premium revenue for overhead costs and profitability.
Through its growing scale and technology-driven efficiencies, Oscar Health has consistently reduced overhead costs as a percentage of revenue, which should lead to a nice profit inflection in 2026. It generated $700 million in operating income last quarter, with expectations of $250 million to $450 million in operating earnings for all of 2026 due to seasonality in healthcare utilization costs.
Over the long term, we should see continued progress in lowering its overhead costs as a percentage of revenue through greater nationwide scale. Combined with rapid revenue growth -- premium revenue is up 2,770% since 2021 -- Oscar Health can see a huge profit increase in the years ahead. A 5% profit margin on $50 billion in revenue is $2.5 billion in earnings, which could occur within the next five years.
Oscar Health stock is set up to crush the market in the years ahead if it simply keeps up its path of profit margin expansion and market share gains in health insurance payors.
Right now, the stock trades at a market cap of $6.6 billion. That results in a price-to-earnings multiple of 15, based on the high end of its 2026 earnings guidance, but, more importantly, just 2.5 times my profit assumption for when Oscar Health reaches $50 billion in revenue. That will not happen in 2026, but patient investors should be able to watch a huge profit inflection unfold over the decade ahead, leading to potentially massive stock price appreciation for investors who hold Oscar Health stock and never sell.
Before you buy stock in Oscar Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Oscar Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $465,733! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,313,467!
Now, it’s worth noting Stock Advisor’s total average return is 985% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 29, 2026. *
Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"OSCR's path to $50B premiums and 5% margins within five years faces steeper regulatory and competitive hurdles than the article acknowledges, capping upside from current levels."
The article highlights Oscar Health's (OSCR) rapid ACA membership growth to 3.2 million and projected $19B 2026 revenue, arguing tech efficiencies will drive margins toward 5% on $50B premiums for a multibagger outcome at 2.5x forward earnings. Yet it underplays execution risk in shifting to employer-funded plans amid 75M potential customers, ACA loss-ratio caps at 80%, and competition from scaled incumbents. Seasonality in medical costs and regulatory shifts could delay the profit inflection beyond 2026 guidance of $250-450M operating earnings. Valuation at $6.6B market cap assumes flawless share gains in a $1.6T market without margin compression from healthcare inflation or enrollment churn.
If OSCR sustains 50%+ membership growth and hits nationwide scale, the 15x 2026 P/E could compress further as earnings compound to $2.5B, validating the re-rating thesis despite near-term volatility.
"The article's $2.5B profit projection on $50B revenue violates the ACA's 80/20 loss ratio constraint unless Oscar achieves MLR compression that no health insurer has sustained long-term."
Oscar Health's 50% YoY member growth is real and the ACA marketplace tailwind is structural. But the article conflates revenue growth with profit growth recklessly. It assumes Oscar reaches $50B in premiums at a 5% margin—that's 500bps above the 80/20 ACA rule allows for *total* overhead AND profit combined. The math only works if Oscar achieves unprecedented operational leverage or if medical loss ratios compress dramatically. Neither is guaranteed. The $700M operating income cited appears to be a single quarter; annualized guidance of $250-450M for 2026 suggests significant seasonality or margin compression. At 15x forward P/E on 2026 guidance, the stock isn't cheap—it's priced for flawless execution in a regulated market with structural margin caps.
If Oscar's tech platform genuinely reduces medical loss ratios below industry average (plausible given their digital-first model), and employer-funded individual plans scale as management projects, the $50B revenue scenario at acceptable margins becomes credible, and today's valuation is a steal.
"Oscar Health's valuation hinges less on top-line growth and more on whether its technology can sustainably outperform traditional actuarial models in the volatile ACA marketplace."
OSCR is attempting a classic 'growth-to-value' pivot, banking on operating leverage to turn its tech-stack efficiency into bottom-line profitability. While the ACA marketplace growth is undeniable, the article glosses over the 'Medical Loss Ratio' (MLR) risk. In insurance, scale is a double-edged sword; if their actuarial models fail to account for rising utilization or adverse selection in the individual market, that 20% overhead buffer evaporates instantly. Trading at roughly 15x 2026 forward earnings is aggressive for a company still proving its long-term underwriting discipline. I am neutral; the tech-first narrative is compelling, but the regulatory and actuarial volatility in the ACA segment is often underestimated by retail-focused analysis.
If Oscar’s proprietary tech platform actually reduces administrative friction and medical costs faster than incumbents, they could maintain a structural cost advantage that allows them to underprice competitors while maintaining superior margins.
"Oscar’s bullish thesis hinges on an unlikely, sustained margin inflection tied to aggressive scale; without regulatory stability and proven payer willingness to subsidize growth, the upside is far less assured."
While the piece paints Oscar Health as a once-in-a-decade profit engine, the bullish thesis rests on fragile underpinnings. OSCR’s profitability hinges on sustained, rapid premium growth and a multi-year margin expansion that ignores regulatory realities. Insurers operate under an 80% loss-ratio cap and must cover overhead within a tight band; even with tech-driven efficiency, achieving meaningful operating income requires scaling to tens of millions of members and maintaining favorable cost trends. The article’s path to $50B in revenue by the mid-2020s implies SMB and employer-funded penetration that isn’t proven, plus potential price pressure and competitive disinflation risks. A shock to medical costs or policy changes could derail the inflection.
The strongest counterpoint is that profitability in this space has historically eluded new entrants; even with scale, margin expansion is uncertain, and the stock could reprice on regulatory or medical-cost shocks.
"Employer-funded plans bypass ACA MLR caps, enabling the margin expansion Claude deems impossible."
Claude overlooks that employer-funded plans, which Oscar is targeting for scale, fall outside ACA's strict 80/20 MLR requirements. This opens a path to higher margins without violating regulations on individual marketplace business. Combined with Grok's point on 75M potential customers, the $50B premium target at 5% margins becomes more plausible if this segment grows faster than expected, though medical cost inflation remains a wildcard.
"Employer-plan margins are higher but riskier; medical cost inflation could compress them before scale offsets the ACA MLR cap."
Grok's employer-plan carve-out is the crux, but needs stress-testing. Non-ACA plans still face medical cost inflation and adverse selection risk—Oscar's tech doesn't inoculate against utilization shocks. More critically: employer plans have different churn dynamics and price sensitivity than ACA. If Oscar scales employer business but medical costs spike (say, 8-10% annually), margin compression hits faster than the 2026 inflection assumes. Nobody's quantified how much employer revenue Oscar needs to offset ACA's regulatory margin ceiling.
"Monetizing the '+Oscar' tech platform as SaaS revenue provides a path to margin expansion that bypasses ACA medical loss ratio caps entirely."
Claude is right to pivot to the employer segment, but we are missing the 'tech-as-a-service' angle. Oscar isn't just an insurer; they are selling their '+Oscar' platform to other carriers. If they successfully monetize the tech stack as a high-margin SaaS revenue stream, the 80/20 MLR constraint becomes irrelevant for that portion of income. This creates a dual-engine model that decouples valuation from pure underwriting risk, justifying a higher multiple than a standard insurance company.
"The SaaS monetization alone isn’t proven to unlock a high multiple; without durable SaaS margins, the high-valuation thesis risks a derating from underwriting volatility."
Gemini's 'tech-as-a-service' angle is intriguing, but it glosses over unit economics and customer concentration risk. Monetizing Oscar's platform as pure SaaS requires durable pricing power and ongoing R&D; carrier adoption could be slow, and revenue mix may stay tied to underwriting profits that could disappoint if MLR or utilization spikes. In short, the dual-engine narrative may not justify a high multiple without proven SaaS margins.
The panel's net takeaway is that while Oscar Health's growth is undeniable, its path to profitability and high margins is uncertain and risky, with significant execution challenges and regulatory constraints.
Successfully scaling its employer-funded plans and monetizing its tech stack as a high-margin SaaS revenue stream could provide a path to higher margins and valuation for Oscar Health.
Regulatory constraints, particularly the 80% Medical Loss Ratio cap, and potential medical cost inflation and utilization shocks pose significant risks to Oscar Health's profitability and margin expansion.